Neurocrine Biosciences (NBIX) : Mondays money flow data in Neurocrine Biosciences (NBIX) suggests that the bulls made the most of the weakness in the stock. The inflow of money into the stock on upticks was $0.17 million, whereas, $0.02 million worth of transactions were done on downticks. The ratio between the two, uptick and downtick stood at 7.12, in favor of the bulls. The total money flow into the stock was $0.15 million clearly indicating that the smart money has been buying into the stock on weakness.
In comparison, the money flow in block deals was $0 million. The total value of block trades done on upticks was $0 million. Neurocrine Biosciences (NBIX) fell $0.05 and traded at $48.33, down -0.1% for the day, over previous days close. On a weekly basis, the shares are -3.28% over the previous weeks close.
Shares of Neurocrine Biosciences Inc. rose by 0.27% in the last five trading days and 5.13% for the last 4 weeks. Neurocrine Biosciences Inc. is up 6.77% in the last 3-month period. Year-to-Date the stock performance stands at -13.86%.
Neurocrine Biosciences (NASDAQ:NBIX): During Mondays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $48.46 and $48.13 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $49.18. The buying momentum continued till the end and the stock did not give up its gains. It closed at $48.73, notching a gain of 0.72% for the day. The total traded volume was 405,173 . The stock had closed at $48.38 on the previous day.
In a related news, The Securities and Exchange Commission has divulged that Nevinny Corinne H, director of Neurocrine Biosciences Inc, had unloaded 5,000 shares at an average price of $48.54 in a transaction dated on August 8, 2016. The total value of the transaction was worth $242,700.
Neurocrine Biosciences, Inc. is engaged in the development of pharmaceutical products focused on neurological and endocrine based diseases and disorders. The Companys two lead late-stage clinical programs are elagolix, a gonadotropin releasing hormone (GnRH) antagonist for womens health that is partnered with AbbVie Inc. (AbbVie), and a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. elagolix is in clinical trials for the treatment of Endometriosis and Uterine Fibroids. VMAT2 (NBI-98854) is a VMAT2 inhibitor in clinical trials for the treatment of tardive dyskinesia. Corticotropin-Releasing Factor (CRF) receptor antagonist (NBI-77860) is indicated for the treatment of Classic Congenital Adrenal Hyperplasia. NBI-77860 is a selective, orally-active, non-peptide CRF receptor antagonist.